
Keywords: Left ventricular mass (LVM); LVM regression; cardiovascular mortality; chronic kidney disease (CKD); left ventricular hypertrophy; surrogate endpoint; surrogate outcome; cardioprotection; erythropoiesis-stimulating agent (ESA); renin-angiotensin-aldostero